These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, Crompton AE, Murphy SA, Lanz H, Mercuri MF, Antman EM, Braunwald E, ENGAGE AF-TIMI 48 Investigators. Circ Arrhythm Electrophysiol; 2017 Jan; 10(1):. PubMed ID: 28077507 [Abstract] [Full Text] [Related]
23. Clinical outcomes in patients with atrial fibrillation treated with digoxin, according to the presence of heart failure: Insights from the MISOAC-AF trial. Botis M, Kartas A, Samaras A, Akrivos E, Vrana E, Liampas E, Papazoglou AS, Moysidis DV, Papanastasiou A, Baroutidou A, Karvounis H, Tzikas A, Parissis J, Drakos SG, Giannakoulas G. Hellenic J Cardiol; 2022 Jan; 68():25-32. PubMed ID: 36037999 [Abstract] [Full Text] [Related]
25. Outcomes of Rate-Control Treatment in Patients With Atrial Fibrillation and Heart Failure - A Nationwide Cohort Study. Yu HT, Yang PS, Lee H, You SC, Kim TH, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B. Circ J; 2018 Feb 23; 82(3):652-658. PubMed ID: 29142156 [Abstract] [Full Text] [Related]
27. Digoxin Impact on Heart Failure Patients with Atrial Fibrillation. Gerakaris A, Mulita F, Koniari I, Artopoulou E, Mplani V, Tsigkas G, Abo-Elseoud M, Kounis N, Velissaris D. Med Arch; 2022 Feb 23; 76(1):23-28. PubMed ID: 35422570 [Abstract] [Full Text] [Related]
28. Digoxin and Mortality in Patients With Atrial Fibrillation. Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, Ridefelt P, Lawrence JH, De Caterina R, Vinereanu D, Hanna M, Flaker G, Al-Khatib SM, Hohnloser SH, Alexander JH, Granger CB, Wallentin L, ARISTOTLE Committees and Investigators. J Am Coll Cardiol; 2018 Mar 13; 71(10):1063-1074. PubMed ID: 29519345 [Abstract] [Full Text] [Related]
29. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Fauchier L, Grimard C, Pierre B, Nonin E, Gorin L, Rauzy B, Cosnay P, Babuty D, Charbonnier B. Am J Cardiol; 2009 Jan 15; 103(2):248-54. PubMed ID: 19121446 [Abstract] [Full Text] [Related]
30. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, Held C, Hylek EM, Leonardi S, Hanna M, Ezekowitz JA, Siegbahn A, Granger CB, Wallentin L. Circulation; 2018 Oct 16; 138(16):1666-1676. PubMed ID: 29871978 [Abstract] [Full Text] [Related]
31. Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. Elayi CS, Shohoudi A, Moodie E, Etaee F, Guglin M, Roy D, Khairy P, AF-CHF Investigators. Int J Cardiol; 2020 Aug 15; 313():48-54. PubMed ID: 32320783 [Abstract] [Full Text] [Related]
32. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. van Diepen S, Hellkamp AS, Patel MR, Becker RC, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW. Circ Heart Fail; 2013 Jul 15; 6(4):740-7. PubMed ID: 23723250 [Abstract] [Full Text] [Related]
33. Digoxin Initiation and Outcomes in Patients with Heart Failure (HFrEF and HFpEF) and Atrial Fibrillation. Singh S, Moore H, Karasik PE, Lam PH, Wopperer S, Arundel C, Tummala L, Anker MS, Faselis C, Deedwania P, Morgan CJ, Zeng Q, Allman RM, Fonarow GC, Ahmed A. Am J Med; 2020 Dec 15; 133(12):1460-1470. PubMed ID: 32603789 [Abstract] [Full Text] [Related]
34. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM, ROCKET AF Steering Committee & Investigators, ROCKET AF Steering Committee Investigators. J Am Heart Assoc; 2016 Mar 08; 5(3):e002197. PubMed ID: 26955859 [Abstract] [Full Text] [Related]
36. Atrial Fibrillation can adversely impact Heart Failure with Preserved Ejection Fraction by its association with Heart Failure Progression and Mortality: A Post-Hoc Propensity Score-Matched Analysis of the TOPCAT Americas Trial. Saksena S, Slee A, Natale A, Lakkireddy DR, Shah D, Di Biase L, Lewalter T, Nagarakanti R, Santangeli P. Europace; 2023 May 19; 25(5):. PubMed ID: 37078691 [Abstract] [Full Text] [Related]
37. Increased All-Cause Mortality Associated With Digoxin Therapy in Patients With Atrial Fibrillation: An Updated Meta-Analysis. Chen Y, Cai X, Huang W, Wu Y, Huang Y, Hu Y. Medicine (Baltimore); 2015 Dec 19; 94(52):e2409. PubMed ID: 26717399 [Abstract] [Full Text] [Related]
39. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). Aisenberg J, Chatterjee-Murphy P, Friedman Flack K, Weitz JI, Ruff CT, Nordio F, Mercuri MF, Choi Y, Antman EM, Braunwald E, Giugliano RP. Circ Cardiovasc Qual Outcomes; 2018 May 19; 11(5):e003998. PubMed ID: 29748353 [Abstract] [Full Text] [Related]
40. Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. Sethi NJ, Nielsen EE, Safi S, Feinberg J, Gluud C, Jakobsen JC. PLoS One; 2018 May 19; 13(3):e0193924. PubMed ID: 29518134 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]